Pentadeca Arginate (PDA) – Kodiac biolabs

Our opinion on this compoundNiche research probe

28/100

A formulation variant of BPC-157 with no independent pharmacological literature or novel mechanism

Look, here’s the thing about PDA: the peptide is BPC-157. Exactly. Same sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), same molecular weight at 1419.55 for the free peptide, same pharmacological targets, same mechanism. What’s different is the counterion (arginate instead of acetate), which vendors argue improves aqueous stability and extends lyophilized shelf life. Thats a real formulation win for labs that want better consistency in their peptide preps. It is not a new compound.

This matters a lot for scoring. PDA has no independent published preclinical record. Zero papers. The entire pharmacological basis for PDA comes from the BPC-157 acetate literature, which itself has a serious problem: it’s almost entirely generated by a single research group (Sikiric, University of Zagreb). We’ve covered this in detail in the BPC-157 monograph. The tendon healing, vascular reorganization, GI mucosal protection signals are real preclinical observations, but independent multi-lab replication is thin, and human evidence is essentially absent. When you’re rating PDA on evidence quality, you’re rating a compound with no publications of its own, built on top of a literature with existing replication issues.

On differentiation, PDA is strictly downstream of BPC-157 acetate, not above it. The only dimension where PDA has an argument is formulation stability, and even that claim is based on vendor literature rather than published comparative stability studies under controlled lab conditions. An investigator choosing between BPC-157 acetate and PDA is making a handling decision, not a scientific one. There is no pharmacological reason to expect different outcomes between the two.

We do give some credit for bench value. If you’re running an active BPC-157 research program, PDA offers a potentially more stable working stock, which has genuine practical value in peptide work where gradual degradation can introduce noise into your data. Thats not nothing. But it doesnt elevate PDA into meaningful independent research territory; the upstream BPC-157 evidence questions don’t go away because the salt counterion changed.

What we don’t like: this is a textbook vendor catalog phenomenon. PDA emerged in 2023-2024 as peptide suppliers differentiated product lines, not from any published scientific advance. The improved stability framing is a marketing angle until head-to-head comparative stability data under real lab conditions actually gets published. Investigators should treat PDA as a formulation option within an existing BPC-157 research program, not as an independent compound warranting its own inquiry. If you’re not already running BPC-157 work, PDA gives you no scientific reason to start.

Novelty: 35
Mechanism promise: 40
In-category differentiation: 18
Evidence quality: 15
Translational signal: 20
Research bench value: 38

Rationale PDA is pharmacologically identical to BPC-157 acetate; its only differentiator is counterion choice for handling stability. With zero independent published data and no mechanism beyond what the Sikiric group established for the parent peptide, PDA scores low across novelty, evidence, and differentiation, landing well below the BPC-157 calibration anchor.

Arginate salt analog of BPC-157

A research-grade arginate salt formulation of the pentadecapeptide BPC-157 sequence, formulated for improved aqueous stability and shelf life relative to acetate-salt parent.

Abstract

Pentadeca Arginate (PDA; the pentadecapeptide Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val formulated as the arginate salt; the underlying peptide is identical to BPC-157, CAS 137525-51-0; molecular formula C62H98N16O22 free peptide; molecular weight 1419.55 free peptide; the arginate salt adds counterions and is formulated for improved stability) is a research-grade alternative formulation of the BPC-157 pentadecapeptide that has emerged in research-grade peptide vendor catalogs in 2023 to 2024 as a stabilized analog. The pharmacological argument is that the arginate counterion improves aqueous solubility and extends shelf life of the lyophilized solid relative to acetate-salt BPC-157, which is the standard formulation; the underlying peptide sequence and pharmacology are identical, and any differences between PDA and BPC-157 in vivo are attributable to formulation rather than to a different molecule. The published preclinical record on the BPC-157 sequence is summarized in the Kodiac BPC-157 monograph (KDC-MN-002): tendon and ligament healing, vascular reorganization, gastrointestinal mucosal protection, dopaminergic system modulation, broad rodent injury-recovery activity, with the limitation that the literature is dominated by the originating Sikiric group at the University of Zagreb. PDA has no independent published preclinical record beyond the parent BPC-157 work; vendor literature emphasizes formulation stability claims rather than novel pharmacology. Investigators should not assume that PDA differs pharmacologically from BPC-157 acetate; the choice between formulations should be made on stability and handling considerations. Reconstitution and dosing follow BPC-157: bacteriostatic water for injection, refrigerated storage of reconstituted solution, parenteral administration at 250 to 500 mcg per dose. The compound is research-grade and not approved by any regulatory authority for human or veterinary use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1338Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.